The value of time in therapeutic range in the prediction of outcomes at a populational level in patients treated with vitamin K antagonists

被引：1
作者：
Caldeira, Daniel [1 ,2 ]
机构：
[1] Univ Lisbon, Fac Med, Lab Farmacol Clin & Terapeut, Av Prof Egas Moniz, P-1649028 Lisbon, Portugal
[2] Inst Med Mol, Clin Pharmacol Unit, Lisbon, Portugal
来源：
CURRENT MEDICAL RESEARCH AND OPINION | 2018年 / 34卷 / 03期
关键词：
ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; ADVERSE EVENTS; WARFARIN; METAANALYSIS; INTENSITY; QUALITY; RATIO;
D O I：
10.1080/03007995.2017.1411794
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：499 / 500
页数：2
相关论文
共 15 条
  • [1] Meta-Analysis to Assess the Quality of Warfarin Control in Atrial Fibrillation Patients in the United States
    Baker, William L.
    Cios, Deborah A.
    Sander, Stephen D.
    Coleman, Craig I.
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2009, 15 (03): : 244 - 252
  • [2] Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis
    Caldeira, Daniel
    David, Claudio
    Costa, Joao
    Ferreira, Joaquim J.
    Pinto, Fausto J.
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2018, 4 (02) : 111 - 118
  • [3] The era of the novel oral anticoagulants in Portugal
    Caldeira, Daniel
    Ferreira, Joaquim Jose
    Pinto, Fausto Jose
    [J]. REVISTA PORTUGUESA DE CARDIOLOGIA, 2017, 36 (7-8) : 577 - 578
  • [4] Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira, Daniel
    Cruz, Ines
    Morgado, Goncalo
    Stuart, Bruno
    Gomes, Ana Catarina
    Martins, Cristina
    Joao, Isabel
    Pereira, Helder
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (08) : 972 - 976
  • [5] Evaluation of time in therapeutic range in anticoagulated patients: A single-center, retrospective, observational study
    Caldeira D.
    Cruz I.
    Morgado G.
    Stuart B.
    Gomes C.
    Martins C.
    João I.
    Pereira H.
    [J]. BMC Research Notes, 7 (1)
  • [6] Comparing patient-level and site-level anticoagulation control as predictors of adverse events
    Cancino, Ramon S.
    Hylek, Elaine M.
    Reisman, Joel I.
    Rose, Adam J.
    [J]. THROMBOSIS RESEARCH, 2014, 133 (04) : 652 - 656
  • [7] Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials
    Carmo, Joao
    Ferreira, Jorge
    Costa, Francisco
    Carmo, Pedro
    Cavaco, Diogo
    Carvalho, Salome
    Morgado, Francisco
    Adragao, Pedro
    Mendes, Miguel
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 244 : 196 - 201
  • [8] Educational Intervention Improves Anticoagulation Control in Atrial Fibrillation Patients: The TREAT Randomised Trial
    Clarkesmith, Danielle E.
    Pattison, Helen M.
    Lip, Gregory Y. H.
    Lane, Deirdre A.
    [J]. PLOS ONE, 2013, 8 (09):
  • [9] Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
    Connolly, Stuart J.
    Pogue, Janice
    Eikelboom, John
    Flaker, Gregory
    Commerford, Patrick
    Franzosi, Maria Grazia
    Healey, Jeffrey S.
    Yusuf, Salim
    [J]. CIRCULATION, 2008, 118 (20) : 2029 - 2037
  • [10] Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation
    Liu, Shuqian
    Li, Xiaoyan
    Shi, Qian
    Hamilton, Melissa
    Friend, Keith
    Zhao, Yingnan
    Horblyuk, Ruslan
    Hede, Shalini
    Shi, Lizheng
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (03) : 415 - 421
12